Table 1.

Characteristics of the patients (median, range)

	n	Age (years)	Duration of therapy (years)	CD4+ T cells, at time of study, %	VL at time of study, copies/ml	Age at initiation of therapy (years)	CD4+ T cells at initiation of therapy, %	VL at initiation of therapy, copies/ml
USP	12	8·6 (5·0–10·2)	n.a.	27 (23–41)	453 (123–41 600)	n.a.	n.a.	n.a.
UP	16	8·4 (1·7–15·3)	n.a.	16 (4–33)	90 100 (24 700–>1 000 000)	n.a.	n.a.	n.a.
FS	18	8·7 (4·9–16·5)	3·3 (1·5–4·4)	31 (23–51)	< 50	5·2 (1·8–14·1)	11·5 (0–31)	164 500 (23 000–>750 000)

FS, full viral suppression; n.a., not applicable; UP, untreated progressors; USP, untreated slow progressors; VL, viral load.